Appili Therapeutics Inc Class A (APLIF)
OTHER OTC:APLIF
APLIF Stock Chart & Stats
$0.01
>-$0.01(-8.10%)
At close: 4:00 PM EST
$0.01
>-$0.01(-8.10%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume100.00
Average Volume (3M)43.77K
Market Cap
$1.85M
Enterprise Value$14.82M
Total Cash (Recent Filing)$212.75K
Total Debt (Recent Filing)$12.46M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding128,366,120
10 Day Avg. Volume6,020
30 Day Avg. Volume43,769
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.39
Price to Sales (P/S)5.13
P/FCF Ratio-1.70
Enterprise Value/Market Cap8.02
Enterprise Value/Revenue71.81
Enterprise Value/Gross Profit74.23
Enterprise Value/Ebitda-9.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Infectious-disease Focused PipelineA clear, specialized focus on antibacterial, antiviral, and antifungal programs concentrates R&D resources and expertise. That positioning can attract targeted grants, partnerships, and regulatory priority in preparedness initiatives, supporting durable program funding and strategic clarity.
Strong Revenue Growth RateHigh reported revenue growth percentage signals improving cash inflows or milestone recognition versus a low base. If sustained through continued program advancement and funding wins, this trend supports stronger near-term financing profiles and validates progress in development-stage commercial activity.
Improving Cash Flow TrendAn improvement in operating and free cash flow versus prior years indicates better cash discipline or timing of receipts. While not yet self-funding, this trend reduces immediate financing pressure and suggests management has begun stabilizing cash consumption over a durable multi-quarter horizon.
Bears Say
Stressed Balance Sheet / Negative EquityNegative equity and sizable debt relative to a very small asset base materially constrain financial flexibility. This structural weakness raises refinancing and covenant risks, increases likelihood of dilutive financings, and limits the company's ability to self-fund clinical programs over the medium term.
Persistent Operating LossesSustained negative net income and operating losses deplete cash reserves and lengthen reliance on external capital. Over months this undermines runway and forces trade-offs on program funding, potentially delaying development timelines and increasing execution risk for long-term product commercialization.
Reliance On External FundingA business model dependent on grants, collaborations, and equity financing creates structural funding variability and dilution risk. Absent commercial product revenue, sustained progress hinges on winning partnerships or market access to capital, which can be cyclic and uncertain over multi-quarter horizons.
Appili Therapeutics Inc Class A News
APLIF FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is $1.85M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Jul 01, 2026 which is in 95 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Feb 12, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.005.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 128,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in APLIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.